The combined company will have 200 ANDA’s (worth $120B in branded sales ) and 70 P-IV challenges. US portfolio overlap was characterized as minimal with no actual figure given.
Bruce Downey said Teva had tied to acquire BRL on two prior occasions.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”